NCT04338269 2026-03-19
CONTACT-03
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
14 trialsNCT05411081 2026-03-19
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02496208 2026-03-18
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03793166 2026-03-18
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04071223 2026-03-18
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04514484 2026-03-18
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07227402 2026-03-16
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05122546 2026-03-05
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07293351 2026-03-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05048212 2026-03-02
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05536141 2026-02-27
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting